| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. | N Engl J Med | 2013 | 18.08 |
| 2 | BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. | Cancer Res | 2012 | 2.14 |
| 3 | Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine. | J Am Acad Dermatol | 2011 | 1.97 |
| 4 | Cancer therapy: Tumours switch to resist. | Nature | 2012 | 0.78 |